Etie Moghissi, MD

Etie Moghissi, MD
Medical Director, Diabetes Care Center at Centinela Hospital, Inglewood, CA; Co-chair, American College of Endocrinology Task Force on Inpatient Diabetes and Metabolic Control

Address: Etie Moghissi, MD, FACE, Medical Director, Diabetes Care Center at Centinela Hospital, 501 East Hardy Street, Suite 110, Inglewood, CA 90301; e-mail emoghissi@pol.net

The author has indicated that she is on the speakers’ bureaus of the GlaxoSmithKline, Novo Nordisk, and Pfizer corporations.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Etie Moghissi, MD
Medical Director, Diabetes Care Center at Centinela Hospital, Inglewood, CA; Co-chair, American College of Endocrinology Task Force on Inpatient Diabetes and Metabolic Control

Address: Etie Moghissi, MD, FACE, Medical Director, Diabetes Care Center at Centinela Hospital, 501 East Hardy Street, Suite 110, Inglewood, CA 90301; e-mail emoghissi@pol.net

The author has indicated that she is on the speakers’ bureaus of the GlaxoSmithKline, Novo Nordisk, and Pfizer corporations.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Etie Moghissi, MD
Medical Director, Diabetes Care Center at Centinela Hospital, Inglewood, CA; Co-chair, American College of Endocrinology Task Force on Inpatient Diabetes and Metabolic Control

Address: Etie Moghissi, MD, FACE, Medical Director, Diabetes Care Center at Centinela Hospital, 501 East Hardy Street, Suite 110, Inglewood, CA 90301; e-mail emoghissi@pol.net

The author has indicated that she is on the speakers’ bureaus of the GlaxoSmithKline, Novo Nordisk, and Pfizer corporations.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.